Real-world effectiveness and safety of dupilumab therapy in children ≤6 years with uncontrolled persistent asthma: a propensity-matched retrospective cohort study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Efficacy and Safety of Dupilumab in Young Children (≤6 Years) with Uncontrolled Persistent Asthma: A Retrospective Cohort Analysis with Propensity Score Matching

  • By

  • Ahlam Mazi

  • Azizah Aljohany

  • Michele Fouad

  • Hanaa Hamadallah

  • Esraa M. Bukhari

  • Doaa Bayomi

  • Samahir Alsulaimani

  • Nour Gazzaz

  • Muhannad Sharara

  • Monica Dobs

  • June 15, 2026

Share

  • 1

    Dupilumab is a biological agent effective in older children with uncontrolled asthma but lacks data for children aged six years and younger.

  • 2

    A retrospective cohort analysis compared outcomes in children ≤6 years on dupilumab plus standard treatment versus standard treatment alone.

  • 3

    Dupilumab therapy was associated with reduced acute exacerbations, oral corticosteroid use, and emergency room visits at 6 and 12 months.

  • 4

    The risk of anaphylaxis was higher in children receiving dupilumab compared to those on standard treatment alone.

  • 5

    This study provides real-world evidence on the efficacy and safety of dupilumab for managing uncontrolled asthma in young children.

Original Source(s)

Real-world effectiveness and safety of dupilumab therapy in children ≤6 years with uncontrolled persistent asthma: a propensity-matched retrospective cohort study

  • by Ahlam Mazi, Azizah Aljohany, Michele Fouad, Hanaa Hamadallah, Esraa M. Bukhari, Doaa Bayomi, Samahir Alsulaimani, Nour Gazzaz, Muhannad Sharara, Monica Dobs

  • June 15, 2026

Related Content

Accuracy and stability of DeepSeek-R1 and GPT-4o on pediatric questions

Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor

Association of serum growth differentiation factor 11 with asthma severity, inflammation, and airway remodeling in pediatric patients